⌕
Stoke Therapeutics · STOK · Nasdaq
Tenet 50 · Mixed
Compare
$26.41−0.83%At closeTenet 50 · Mixed
$26.41−0.22 (−0.83%)
At close: Nov 17, 2026, 4:00 PM ET· Nasdaq · USD

Stoke Therapeutics (STOK) News

What's actually happening: chronological and provenance-stamped. News is context, not a signal.

Sources News publishers NewsHow we compute thisNot investment advice

The percentage on each card is STOK's move today, from the quote feed. It is the same figure on every headline, not the move on that headline's own date.

● Business WireNov 17, 2026 · 16:01 ETCOMPANY'S OWN WORDS
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine and has a lead investigat…

STOK −0.8% todayRead at source ↗
● Seeking AlphaOct 30, 2026 · 01:58 ET
Stoke Therapeutics, Inc. (STOK) Q3 2026 Earnings Call Transcript

Stoke Therapeutics, Inc. (STOK) Q3 2026 Earnings Call Transcript…

STOK −0.8% todayRead at source ↗
● MarketBeatOct 29, 2026 · 22:15 ET
Stoke Therapeutics Q3 Earnings Call Highlights

Stoke Therapeutics NASDAQ: STOK said its Phase III EMPEROR trial of zorevunersen in Dravet syndrome is advancing toward a planned third-quarter 2027 data readout, while the company prepares for a potential U.S. regulator…

STOK −0.8% todayRead at source ↗
● Zacks Investment ResearchOct 29, 2026 · 20:06 ET
Stoke Therapeutics, Inc. (STOK) Reports Q3 Loss, Tops Revenue Estimates

Stoke Therapeutics, Inc. (STOK) came out with a quarterly loss of $1.08 per share versus the Zacks Consensus Estimate of a loss of $0.88. This compares to a loss of $0.65 per share a year ago.…

STOK −0.8% todayRead at source ↗
● Business WireOct 29, 2026 · 16:01 ETCOMPANY'S OWN WORDS
Stoke Therapeutics Announces Third Quarter 2026 Financial Results and Provides Business Updates

BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine and has a lead investigat…

STOK −0.8% todayRead at source ↗
● GuruFocusOct 22, 2026 · 09:00 ET
Stoke Therapeutics to Host Webcast and Conference Call to Discuss Third Quarter 2026 Business and Financial Updates

[url="]Stoke Therapeutics, Inc.[/url] (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential wit…

STOK −0.8% todayRead at source ↗
● Seeking AlphaOct 19, 2026 · 16:34 ET
Stoke Therapeutics: The Market Misread A Key FDA Win

Stoke Therapeutics is positioned for a pivotal 2027 readout of zorevunersen, potentially the first disease-modifying Dravet syndrome therapy. STOK's cash runway extends to early 2028, supported by $420M in cash and a rec…

STOK −0.8% todayRead at source ↗
● Business WireOct 16, 2026 · 16:20 ETCOMPANY'S OWN WORDS
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine and has a lead investigat…

STOK −0.8% todayRead at source ↗
● Business WireOct 12, 2026 · 08:00 ETCOMPANY'S OWN WORDS
Stoke Therapeutics Presents Data Supporting the Disease-Modifying Potential of STK-002 in Autosomal Dominant Optic Atrophy (ADOA) at the American Academy of Ophthalmology (AAO) 2026 Annual Meeting

BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine, today announced two presen…

STOK −0.8% todayRead at source ↗
● Business WireOct 6, 2026 · 08:00 ETCOMPANY'S OWN WORDS
Stoke Therapeutics Announces Presentations of STK-002, an Investigational Medicine for the Treatment of Autosomal Dominant Optic Atrophy (ADOA), at the American Academy of Ophthalmology (AAO) 2026 Annual Meeting

BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine, today announced two presen…

STOK −0.8% todayRead at source ↗
● Business WireOct 5, 2026 · 07:00 ETCOMPANY'S OWN WORDS
Stoke Therapeutics Announces Completion of Successful Meeting with the FDA to Align on Planned U.S. NDA for Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome

BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine and has a lead investigat…

STOK −0.8% todayRead at source ↗
● Defense WorldSep 28, 2026 · 03:25 ET
Stoke Therapeutics, Inc. $STOK Shares Newly Acquired by Corient Private Wealth LP

Corient Private Wealth LP purchased a new stake in Stoke Therapeutics, Inc. (NASDAQ: STOK) during the second quarter, according to its most recent Form 13F filing with the SEC. The fund purchased 30,823 shares of the com…

STOK −0.8% todayRead at source ↗
● Business WireSep 23, 2026 · 16:01 ETCOMPANY'S OWN WORDS
Stoke Therapeutics Appoints Bo Cumbo to its Board of Directors, Enhancing Commercial Expertise as the Company Advances Zorevunersen Development Toward Potential FDA Approval and Commercialization

BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine and has a lead investigat…

STOK −0.8% todayRead at source ↗
● Defense WorldSep 18, 2026 · 04:34 ET
Squarepoint Ops LLC Acquires Shares of 29,310 Stoke Therapeutics, Inc. $STOK

Squarepoint Ops LLC acquired a new position in Stoke Therapeutics, Inc. (NASDAQ: STOK) in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 29…

STOK −0.8% todayRead at source ↗
● Business WireSep 16, 2026 · 16:01 ETCOMPANY'S OWN WORDS
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine and has a lead investigat…

STOK −0.8% todayRead at source ↗
● Business WireSep 3, 2026 · 19:30 ETCOMPANY'S OWN WORDS
Stoke Therapeutics and Biogen Present Long-Term Clinical Data that Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 16th European Epilepsy Congress (EEC)

BEDFORD, Mass. & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine, and Bio…

STOK −0.8% todayRead at source ↗
● Business WireSep 2, 2026 · 08:00 ETCOMPANY'S OWN WORDS
Stoke Therapeutics to Present at the Cantor Global Healthcare Conference

BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine and has a lead investigat…

STOK −0.8% todayRead at source ↗
● Defense WorldAug 20, 2026 · 03:24 ET
Bank of America Corp DE Buys 336,931 Shares of Stoke Therapeutics, Inc. $STOK

Bank of America Corp DE lifted its stake in shares of Stoke Therapeutics, Inc. (NASDAQ: STOK) by 163.4% in the first quarter, according to the company in its most recent filing with the SEC. The fund owned 543,095 shares…

STOK −0.8% todayRead at source ↗
● Business WireAug 18, 2026 · 16:01 ET
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine and has a lead investigat…

STOK −0.8% todayRead at source ↗

Kept in their own lane. A press release is the company talking, not reporting.

No upcoming events in the feeds.

NVDA31−0.4%
WDAY4−5.8%
EG3−2.0%

Article counts from the last market-wide feed page, across every symbol we track and not just STOK · day move from the quote feed. Equal counts are listed alphabetically, not ranked. Coverage ≠ importance.

The feed is purely chronological. No materiality ranking, no hidden sentiment score. Timestamps are publisher-reported and arrive with no timezone, so they are read and shown on the US market clock (ET); thumbnails come from each article's image field; day moves from the quote feed. Copies of the same story are collapsed on link or normalized headline, and a company's press release is kept over any syndicated copy of it; "company's own words" means the release title leads with the company's name and the wire names no other organisation first as its issuer; "earnings-tied" is a keyword match while a report date is upcoming. Not investment advice.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.